Showing promise in the field of excess body fat therapy, retatrutide presents a distinct approach. Different from many current medications, retatrutide works as a dual agonist, at once targeting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) binding sites. The concurrent stimulation encourages multiple beneficial effe